Title: Human heart valve-derived scaffold improves cardiac repair in a murine model of myocardial infarction

Authors: Long Wan, Yao Chen, Zhenhua Wang, Weijun Wang, Sebastian Schmull, Jun Dong, Song Xue, Hans Imboden, Jun Li

Supplementary information



Figure S1

Supplementary Figure S1 | The purity of isolated murine BM c-kit+ cells. Murine BM was flushed from femurs and tibias on day 3 after MI. Following density gradient sedimentation, the c-kit+ cells were positively selected using magnetic activated cell sorting (MACS). The purity of isolated c-kit+ cells is around 85%, as determined by an Accuri C6 flow cytometer with CFlow Plus Software. Data shown are representative of 3 independent experiments.

Figure S2



Supplementary Figure S2 | The c-kit+ cell-seeded hHVS is superior to hHVS alone in improving cardiac function. (A-D): Comparisons of echocardiographic parameters of MI (without patch implantation), hHVS (MI with implantation of the hHVS alone), hHVS + c-kit+ (MI with implantation of c-kit+ cell-seeded hHVS), and sham groups 4 weeks after MI/implantation. LVIDd, end-diastolic left ventricular dimension; LVIDs, end-systolic left ventricular dimension; LVEDV, left ventricular end-diastolic volume; LVESV, left ventricular end-systolic volume. MI, n=10; hHVS, n=10; hHVS + c-kit+, n=10; sham, n=7.

Figure S3



Supplementary Figure S3 | No increased infiltration of CD45+ leucocytes after implantation of hHVS or c-kit+ cell-seeded hHVS. HE staining (a, b) and immunofluncent staining (c) showing that an increased infiltration of CD45+ leucocytes (in green) into infarcted myocardium was not additionally induced 4 weeks after implantation of the hHVS alone or c-kit+ cell-seeded hHVS. Green and yellow dotted lines indicate the region analyzed for immunofluncent staining and implanted hHVS, respectively. (a), Scale bar, 1 mm; (b, c), Scale bar, 50 µm. Data shown are representative of 5 independent experiments.

Figure S4



Supplementary Figure S4 | Detection of engrafted donor GFP+ cells in the periinfarct myocardia of recipient MI mice. Immunofluorescent staining of heart sections showing engrafted donor GFP+ cells (in green) surrounding the periinfarct myocardia of recipient MI mice 4 weeks after implantation of GFP+c-kit+ cell-seeded hHVS. The GFP+ cell is absent in the infarcted heart of MI mice with or without implantation of the hHVS. Yellow dotted lines indicate the implanted hHVS or GFP+c-kit+ cell-seeded hHVS. Data shown are representative of 5 independent experiments. Nuclei (in blue) are stained with DAPI; Scale bar, 50 µm.

Echocardiography and hemodynamic parameters 4 weeks after cardiac patch implantation				
	MI	hHVS	hHVS+c-kit+	Sham
Echocardiographic examination				
EF (%)	25.27±2.64	38.27±2.57*	58.91±2.93** ^{&&}	68.20±2.27** ^{&&§}
FS (%)	12.27±1.46	18.71±2.54*	30.40±1.81** ^{&&}	37.15±1.76** ^{&&§}
LVIDd (mm)	5.12±0.40	3.91±0.40	3.14±0.09* ^{&&}	2.81±0.23* ^{&&}
LVIDs (mm)	4.49±0.46	3.23±0.23	2.22±0.09* ^{&&}	1.93±0.10** ^{&&}
LV mass (mg)	67.93±12.02	80.90±14.58	40.35±2.25**	42.83±5.02*
LVEDV (µl)	102.00±22.04	103.90±22.38	39.47±2.67** ^{&}	33.83±5.17** ^{&}
LVESV (µl)	79.67±19.87	70.27±21.10	16.98±1.65** ^{&}	11.32±1.90** ^{&} \$
Hemodynamic parameters				
CO (µl/min)	2609 ± 265.3	3689 ± 180.0**	$4860 \pm 148.0^{**}$	$6168 \pm 198.6^{**^{\&\&\$\$}}$
SV (µl)	5.64 ± 0.68	10.80 ± 0.53 **	$14.06 \pm 0.36^{**}$	$17.20 \pm 1.23^{**^{\&\&}}$
LVESP (mmHg)	65.15 ± 3.48	78.33 ± 1.30**	$84.76 \pm 1.57^{**^{\&}}$	81.08± 1.67** ^{&&}
LVEDP (mmHg) dP/dt max (mmHg/s) dP/dt min (mmHg/s)	7.08 ± 0.89	$5.78 \pm 0.79^{**}$	$5.26 \pm 0.85^{**}$	$3.68 \pm 1.52^{**^{\&\&}}$
	2892 ± 218.6	4632 ± 132.7 **	$5010 \pm 89.16^{**}$	$5769 \pm 297.7^{**}$
	-2253 ± 159.0	-3328 ± 85.40**	-3585 ± 76.36**	$-4509 \pm 208.8^{**}$
Tau (ms)	23.28 ± 1.72	13.84 ± 0.59 **	12.63 ± 0.54 **	$9.65 \pm 0.65^{**^{\&\&}}$

Supplementary Table 1

Supplementary Table 1. Echocardiography and hemodynamic parameters (Millar pressure-volume catheter) of MI (without patch implantation), hHVS (MI with implantation of the hHVS alone), hHVS + c-kit+ (MI with implantation of c-kit+ cell-seeded hHVS), and sham groups 4 weeks after MI/implantation. CO= cardiac output; dP/dt max= maximal rate of rise of left ventricular diastolic pressure; dP/dt min= minimal rate of rise of left ventricular diastolic pressure; LVEDV= left ventricular end-diastolic volume; LVEDP=left ventricular end-diastolic pressure; LVESP= left ventricular end-systolic pressure; LVESV= left ventricular end-systolic volume; LVIDd= end-diastolic left ventricular dimension, LVIDs= end-systolic left ventricular dimension; SV= stroke volume; Tau=left ventricular

relaxation time constant. MI, n=10; hHVS, n=10; hHVS + c-kit+, n=10; sham, n=7; *p<0.05, **p<0.01 vs. MI; *p<0.05, **p<0.01 vs. hHVS; *p<0.05, **p<0.01 vs. hHVS + c-kit+.